{"id":5461,"date":"2021-03-31T08:55:47","date_gmt":"2021-03-31T08:55:47","guid":{"rendered":"https:\/\/www.cardiolinkgroup.com\/?p=5461"},"modified":"2021-04-16T07:21:06","modified_gmt":"2021-04-16T07:21:06","slug":"approval-of-a-clinical-trial-to-assess-the-safety-and-performance-of-seraph-100-in-covid-19","status":"publish","type":"post","link":"https:\/\/www.cardiolinkgroup.com\/en\/approval-of-a-clinical-trial-to-assess-the-safety-and-performance-of-seraph-100-in-covid-19\/","title":{"rendered":"Approval of a clinical trial to assess the safety and performance of Seraph 100 in COVID-19"},"content":{"rendered":"

In Spain, more than 75.000 persons have died of COVID-19, predominantly in densely populated regions like Madrid and Barcelona.<\/p>\n\n\n\n

The Spanish Agency of Medicines and Medical Devices (Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios<\/a>) has recently authorized the start of a clinical investigation designed to collect data to assess the safety and performance of Seraph\u00ae<\/sup><\/a> 100 Microbind Affinity Blood Filter (Seraph 100)<\/a> in the treatment of 42 patients with COVID-19. Hospital Cl\u00ednico San Carlos (Madrid) and\u00a0Hospital Universitari Vall d’Hebron\u00a0(Barcelona) will participate in this clinical investigation, together with some German centers.<\/p>\n\n\n\n

Seraph 100 is a single use extracorporeal broadspectrum sorbent hemoperfusion device for reduction of pathogens from the bloodstream. The Seraph 100 filter has been shown in an in-vitro study to provide clearance of coronavirus from the blood. The use of this extracorporeal filter to remove SARS-CoV-2 virus from the blood is expected to reduce the viral load and shorten or even prevent viral sepsis in patients with COVID-19.<\/p>\n\n\n\n

We at Cardiolink Group<\/a>, as Seraph 100’s Spanish distributor, are thrilled to support Exthera Medica<\/a>l and \u00c5KRN Scientific Consulting<\/a> with the implementation of this study to ensure that reliable and accurate data is presented as soon as possible.<\/p>\n\n\n\n

\"coronavirus\"<\/figure><\/div>","protected":false},"excerpt":{"rendered":"

In Spain, more than 75.000 persons have died of COVID-19, predominantly in densely populated regions like Madrid and Barcelona. The Spanish Agency of Medicines and Medical Devices (Agencia Espa\u00f1ola de Medicamentos y Productos Sanitarios) has recently authorized the start of a clinical investigation designed to collect data to assess the safety and performance of Seraph\u00ae […]<\/p>\n","protected":false},"author":1,"featured_media":5452,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"footnotes":""},"categories":[96],"tags":[1312],"class_list":["post-5461","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-icu","tag-coronavirus-treatment"],"acf":[],"aioseo_notices":[],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t